Actualités Karolinska Development Ab - 0P3C | Actions London Stock Exchange

Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease

Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of...

Karolinska Development’s portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005

Karolinska Development’s portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005 STOCKHOLM...

Interim Report - January-June 2024

Interim Report - January-June 2024 STOCKHOLM – 30 August 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim...

Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator

Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator STOCKHOLM, SWEDEN –...

Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone

Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone STOCKHOLM, SWEDEN...

Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection

Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection...

Karolinska Development invests in BOOST Pharma, expanding its portfolio

Karolinska Development invests in BOOST Pharma, expanding its portfolio STOCKHOLM, SWEDEN – May 28, 2024. Karolinska Development AB (Nasdaq...

Karolinska Development’s Annual General Meeting 2024

Karolinska Development’s Annual General Meeting 2024 STOCKHOLM, SWEDEN – May 16, 2024. Karolinska Development AB (publ) (“Karolinska Development”...

Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC

Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC STOCKHOLM, SWEDEN – May 8...

Interim Report - January-March 2024

Interim Report - January-March 2024 STOCKHOLM – 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim...

Notice of Annual General Meeting in Karolinska Development AB (publ)

Notice of Annual General Meeting in Karolinska Development AB (publ) The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048...

Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC

Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC...

Karolinska Development Annual Report 2023 published

Karolinska Development Annual Report 2023 published STOCKHOLM, SWEDEN – March 22, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today...

Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million STOCKHOLM, SWEDEN...

Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units

Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units STOCKHOLM, Sweden, March 14 2024...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Karolinska Development Ab (0P3C)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

0P3C Actualités

Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease

Karolinska Development’s portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005

Interim Report - January-June 2024

Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator

Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone

Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection

Karolinska Development invests in BOOST Pharma, expanding its portfolio

Karolinska Development’s Annual General Meeting 2024

Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC

Interim Report - January-March 2024

Notice of Annual General Meeting in Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC

Karolinska Development Annual Report 2023 published

Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Karolinska Development Ab (0P3C) Actualités

Karolinska Development Ab (0P3C)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

0P3C Actualités

Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease

Karolinska Development’s portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005

Interim Report - January-June 2024

Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator

Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone

Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection

Karolinska Development invests in BOOST Pharma, expanding its portfolio

Karolinska Development’s Annual General Meeting 2024

Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC

Interim Report - January-March 2024

Notice of Annual General Meeting in Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC

Karolinska Development Annual Report 2023 published

Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application